Lack of pharmacokinetic interactions between transdermal rotigotine and oral levodopa/carbidopa

Journal of Clinical Pharmacology

Volumn 49, Issue 9, 2009, Pages 1047-1055

  Braun, Marina ^a   Cawello, Willi ^a   Andreas, Jens Otto ^a   Boekens, Hilmar ^a   Horstmann, Rolf ^a  

^a Schwarz Pharma AG   (Germany)

Author keywords

Dopamine agonist; Drug drug interaction; Levodopa carbidopa; Rotigotine; Transdermal patch

Indexed keywords

CARBIDOPA PLUS LEVODOPA; PARACETAMOL; ROTIGOTINE;

ADULT; AGED; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BACKACHE; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE INCREASE; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INTERACTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EVENING DOSAGE; EXTRASYSTOLE; FEMALE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEMATOMA; HOSPITALIZATION; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORNING DOSAGE; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RESTLESS LEGS SYNDROME; SIDE EFFECT; STEADY STATE; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; AGED; AREA UNDER CURVE; CARBIDOPA; DOPAMINE AGENTS; DOPAMINE AGONISTS; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; RESTLESS LEGS SYNDROME; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 69549135180     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009338481     Document Type: Article

References (21)

1. Olanow CW, Watts RL, Koller WC An algorithm (decision tree) for the management of Parkinsonĝ€™s disease (2001): treatment guidelines. Neurology. 2001 ; 56 (suppl 5). S1 - S88.
2. Bonuccelli U. Comparing dopamine agonists in Parkinsonĝ€ ™s disease. Curr Opin Neurol. 2003 ; 16 (suppl 1). S13 - S19.
3. Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinsonĝ€™s disease. Neurology. 2005 ; 65 (suppl 1). S3 - S5.
4. Neupro (Rotigotine Transdermal System). http://www.fda.gov/cder/foi/ label/2007/021829lbl.pdf. Accessed January 30, 2009.
5. Watts RL, Jankovic J., Waters C., Rajput A., Boroojerdi B., Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007 ; 68: 272-276. (Pubitemid 46148338)
6. Poewe WH, Rascol O., Quinn N., et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinsonĝ€™s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007 ; 6: 513-520.
7. Oertel WH, Benes H., Garcia-Borreguero D., et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med. 2008 ; 9: 228-239.
8. Trenkwalder C., BeneÅ? H., Poewe W., et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2008 ; 7: 595-604.
9. Fargel M., Grobe B., Oesterle E., Hastedt C., Rupp M. Treatment of Parkinsonĝ€™s disease: a survey of patients and neurologists. Clin Drug Invest. 2007 ; 27: 207-218.
10. Allen RP, Picchietti D., Hening WA, Trenkwalder C., Walters AS, Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: a report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003 ; 4: 101-119.
11. Hansen K., Braun M., Horstmann R. Low drug-drug interaction potential of rotigotine [abstract]. J Clin Pharmacol. 2005 ; 45: 1091.
12. Nutt JG, Fellman JH Pharmacokinetics of levodopa. Clin Neuropharmacol. 1984 ; 7: 35-49.
13. Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism. Drugs. 1976 ; 11: 329-377.
14. Evans MA, Broe GA, Triggs EJ, Cheung M., Creasey H., Paull PD Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient. Neurology. 1981 ; 31: 1288-1294.
15. Del Dotto P., Colzi A., Musatti E., et al. Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinsonĝ€ ™s disease. Clin Neuropharmacol. 1997 ; 20: 455-465.
16. Rabey JM, Schwartz M., Graff E., Harsat A., Vered V. The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinsonĝ€ ™s disease. Clin Neuropharmacol. 1991 ; 514-522.
17. Contin M., Riva R., Martinelli P., Albani F., Baruzzi A. No effect of chronic bromocriptine therapy on levodopa pharmacokinetics in patients with Parkinsonĝ€™s disease. Clin Neuropharmacol. 1992 ; 15: 505-508.
18. Rabey JM, Oberman Z., Scharf M., Isakov M., Bar M., Graff E. Bromocriptine blood levels after the concomitant administration of levodopa, amantadine and biperiden in Parkinsonĝ€™s disease. Acta Neurol Scand. 1990 ; 81: 411-415.
19. Kompoliti K., Adler CH, Raman R., et al. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002 ; 58: 1418-1422.
20. Taylor AC, Beerahee A., Citerone DR, et al. Lack of a pharmacokinetic interaction at steady state between ropinirole and L-dopa in patients with Parkinsonĝ€™s disease. Pharmacotherapy. 1999 ; 19: 150-156.
21. Malik M., Andreas J-O., Hnatkova K., et al. Thorough QT/QTc study in patients with advanced Parkinsonĝ€™s disease. Clin Pharmacol Ther. 2008 ; 84: 595-603.